{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:26:45Z","timestamp":1781918805759,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019418","name":"NIHR BRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR302258"],"award-info":[{"award-number":["NIHR302258"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jid.2023.01.033","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T19:45:18Z","timestamp":1678131918000},"page":"1708-1716.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-7927","authenticated-orcid":false,"given":"Antony","family":"Raharja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-9941","authenticated-orcid":false,"given":"Zehra","family":"Arkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4212-4584","authenticated-orcid":false,"given":"Giulia","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1895-6070","authenticated-orcid":false,"given":"Teresa","family":"Tsakok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7793-2090","authenticated-orcid":false,"given":"Tejus","family":"Dasandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-2231","authenticated-orcid":false,"given":"Sarah","family":"Guard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-0711","authenticated-orcid":false,"given":"Arlene","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5539","authenticated-orcid":false,"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3200-0075","authenticated-orcid":false,"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-183X","authenticated-orcid":false,"given":"Jonathan N.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-1144","authenticated-orcid":false,"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-3794","authenticated-orcid":false,"given":"Satveer K.","family":"Mahil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.01.033_bib1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jid.2019.10.011","article-title":"Using implementation science to optimize the uptake of evidence-based medicine into dermatology practice","volume":"140","author":"Ashrafzadeh","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2023.01.033_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamadermatol.2019.4897","article-title":"Comparison of tightly controlled dose reduction of biologics with usual care for patients with psoriasis: a randomized clinical trial","volume":"156","author":"Atalay","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jid.2018.08.012","article-title":"Adalimumab in psoriasis: how much is enough?","volume":"139","author":"Billi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200528010-00002","article-title":"Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions","volume":"28","author":"Bousquet","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.jid.2023.01.033_bib6","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1136\/annrheumdis-2013-203893","article-title":"Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis","volume":"74","author":"Chen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2023.01.033_bib7","first-page":"101","article-title":"Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases","volume":"9","author":"Dreesen","year":"2017","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.jid.2023.01.033_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.15643","article-title":"Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease","volume":"51","author":"Gibson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2023.01.033_bib11","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1017\/cts.2021.789","article-title":"Understanding and applying the RE-AIM framework: clarifications and resources","volume":"5","author":"Holtrop","year":"2021","journal-title":"J\u00a0Clin Transl Sci"},{"key":"10.1016\/j.jid.2023.01.033_bib12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing therapies using therapeutic drug monitoring: current strategies and future perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2023.01.033_bib13","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/art.39169","article-title":"Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis","volume":"67","author":"Jani","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2023.01.033_bib14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2023.01.033_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2023.01.033_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","article-title":"Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial","volume":"77","author":"L\u2019ami","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2023.01.033_bib17","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jid.2023.01.033_bib18","first-page":"127","article-title":"Therapeutic drug monitoring of biologics in psoriasis","volume":"13","author":"Liau","year":"2019","journal-title":"Biologics"},{"key":"10.1016\/j.jid.2023.01.033_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ibd\/izaa102","article-title":"Effect of a practice-wide anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with inflammatory bowel disease","volume":"27","author":"Lyles","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jid.2023.01.033_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.12341","article-title":"Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study","volume":"169","author":"Mahil","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib21","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamadermatol.2014.5479","article-title":"Developing: a therapeutic range of adalimumab serum concentrations in management of psoriasis a step toward personalized treatment","volume":"151","author":"Menting","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2023.01.033_bib24","unstructured":"NHS England. NHS set to save \u00a3150 million by switching to new version of most costly drug, https:\/\/www.england.nhs.uk\/2018\/10\/nhs-set-to-save-150-million-by-switching-to-new-versions-of-most-costly-drug\/; 2018 (accessed January 23, 2022)."},{"key":"10.1016\/j.jid.2023.01.033_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/flgastro-2019-101372","article-title":"UK National Survey of Gastroenterologists\u2019 attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease","volume":"12","author":"Nigam","year":"2021","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.jid.2023.01.033_bib26","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12026-016-8824-8","article-title":"Detection of adalimumab and anti-adalimumab antibodies in patients with rheumatoid arthritis: a comprehensive overview of methodology pitfalls and benefits","volume":"65","author":"Ogri\u010d","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.jid.2023.01.033_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jid.2023.01.033_bib28","first-page":"115","article-title":"Evaluation of therapeutic drug monitoring in the clinical management of patients with rheumatic diseases: data from a retrospective single-center cohort study","volume":"14","author":"Pedersen","year":"2020","journal-title":"Biologics"},{"key":"10.1016\/j.jid.2023.01.033_bib29","first-page":"1","article-title":"Dose-tapering of TNF inhibitors in daily rheumatology practice enables the maintenance of clinical efficacy while improving cost-effectiveness","volume":"3","author":"Salcedo","year":"2015","journal-title":"J\u00a0Pharmacovigilance"},{"key":"10.1016\/j.jid.2023.01.033_bib30","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14712598.2018.1537367","article-title":"Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?","volume":"18","author":"Samaan","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jid.2023.01.033_bib31","first-page":"303","article-title":"Targeted treatment of psoriasis with adalimumab: A critical appraisal based on a systematic review of the literature","volume":"3","author":"Schmitt","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.jid.2023.01.033_bib32","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/09546634.2020.1832649","article-title":"Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey","volume":"33","author":"Schots","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2023.01.033_bib33","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: A retrospective study","volume":"106","author":"Sejournet","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jid.2023.01.033_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib35","first-page":"3011","article-title":"Promising tools to facilitate the implementation of TDM of biologics in clinical practice","volume":"11","author":"Soenen","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jid.2023.01.033_bib36","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: A randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2023.01.033_bib37","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: A randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2023.01.033_bib38","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","article-title":"Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the poetic study","volume":"113","author":"Ungar","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jid.2023.01.033_bib39","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jid.2023.01.033_bib40","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jid.2023.01.033_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636420","article-title":"The first WHO international standard for adalimumab: dual role in bioactivity and therapeutic drug monitoring","volume":"12","author":"Wadhwa","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2023.01.033_bib42","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/apt.13992","article-title":"Intra-patient variability in adalimumab drug levels within and between cycles in Crohn\u2019s disease","volume":"45","author":"Ward","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2023.01.033_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","article-title":"Defining the therapeutic range for adalimumab and predicting response in psoriasis: A multicenter prospective observational cohort study","volume":"139","author":"Wilkinson","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.01.033_bib44","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jid.2018.07.028","article-title":"Defining the therapeutic range for adalimumab and predicting response in psoriasis: a multicenter prospective observational cohort study","volume":"139","author":"Wilkinson","year":"2019","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23001604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23001604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:33:18Z","timestamp":1758303198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23001604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0022202X23001604"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.033","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}